🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against superbug strains of the infection, according to scientists.

A Global Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting over 82 million instances each year. Especially elevated rates are observed in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, the spread of superbugs and the highly restricted available drugs presently on offer.”

Medical experts are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts hope that specific application of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat UTIs, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment emerged from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been outpacing our drug pipeline.”

Research Study Data and Worldwide Availability

Based on data detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which combines two antibiotics. The research involved nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the ability to register and commercialise the drug in many developing nations.

Medical professionals directly involved have voiced optimism. The availability of a single-dose, oral treatment such as this is hailed as a "critical tool" for public health efforts. This is viewed as essential to lessen the impact of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.